Acta Med. 2005, 48: 67-73

https://doi.org/10.14712/18059694.2018.34

Pharmacological Potential of Endothelin Receptors Agonists and Antagonists

Jiří Patočkaa,b, Vladimír Měrkaa, Vratislav Hrdina, Radomír Hrdinac

aUniversity of Defence in Brno, Faculty of Military Health Sciences in Hradec Králové, Department of Toxicology, Hradec Králové, Czech Republic
bUniversity of South Bohemia, České Budějovice, Faculty of Health and Social Studies, Department of Radiology and Toxicology, České Budějovice, Czech Republic
cCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Pharmacology and Toxicology, Hradec Králové, Czech Republic

Received September 1, 2004
Accepted November 1, 2004

References

1. Abassi Z, Ramadan R, Schwartz H, Hoffman A. Therapeutic implications of endothelin antagonists for cardiovascular diseases (Article in Hebrew). Harefuah 2004; 143:47–53, 84.
2. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature (London) 1990; 348:730–2. <https://doi.org/10.1038/348730a0>
3. Bdolah A, Wollberg Z, Fleminger G, Kochva E. SRTX-d, a new native peptide of the endothelin/sarafotoxin family. FEBS Lett 1989; 256:1–3. <https://doi.org/10.1016/0014-5793(89)81706-5>
4. Becker A, Dowdle EB, Hechler U, Kauser K, Donner P, Schleuning WD. Bibrotoxin, a novel member of the endothelin/sarafotoxin peptide family, from the venom of the burrowing asp Atractaspis bibroni. FEBS Lett 1993; 315:100–3. <https://doi.org/10.1016/0014-5793(93)81142-M>
5. Davenport AP, Battistini B. Classification of endothelin receptors and antagonists in clinical development. Clin Sci 2002; 103:1S–3S. <https://doi.org/10.1042/CS103S001S>
6. Davenport AP. Endothelin receptors. In: The IUPHAR Compendium of Receptor Characterisation and Classification, 2nd edn, London: IUPHAR Media, 2000:182–8.
7. Davenport AP, Kuc RE, Hoskins SL, Karet FE, Fitzgerald F. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature. Br J Pharmacol 1994; 113:1303–10. <https://doi.org/10.1111/j.1476-5381.1994.tb17140.x> <PubMed>
8. Davenport AP, Maguire JJ. Of mice and men: advances in endothelin research and first antagonist gains FDA approval. Trends Pharmacol Sci 2002; 23:155–7. <https://doi.org/10.1016/S0165-6147(00)01975-1>
9. D’Orleans-Juste P, Plante M, Honore JC, Carrier E, Labonte J. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 2003; 81:503–10. <https://doi.org/10.1139/y03-032>
10. Gavornik P, Bremserová E, Pilarčíková A. Endotelová dysfunkcia – ústredný klinický problém angiológie a praktickej klinickej medicíny v súčasnosti. Med Milit Slovaca 2003; 5:30–7.
11. Gray AG, Webb DJ. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharm Ther 1996; 72:109–48. <https://doi.org/10.1016/S0163-7258(96)00101-5>
12. Haynes WG. Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease. Clin Sci 1993; 84:485–500. <https://doi.org/10.1042/cs0840485>
13. Howard PG, Plumpton C, Davenport AP. Anatomical localisation and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens 1992; 10:1379–86. <https://doi.org/10.1097/00004872-199211000-00010>
14. Inoue A, Yanagisawa M, Kimura S. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86:2863–7. <https://doi.org/10.1073/pnas.86.8.2863> <PubMed>
15. Karet FE, Kuc RE, Davenport AP. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int 1993; 44:36–42. <https://doi.org/10.1038/ki.1993.210>
16. Kolb E. Endothelins – properties, formation, mechanism of action and significance (Article in German) Z Gesamte Inn Med 1991; 46:355–60.
17. Krum H, Liew D. New and emerging drug therapies for the management of acute heart failure. Intern Med J 2003; 33:515–20. <https://doi.org/10.1046/j.1445-5994.2003.00483.x>
18. Kurnik D, Haviv Y, Kochva E. A snake bite by the Burrowing Asp, Atractaspis engaddensis. Toxicon 1999; 37:223–7. <https://doi.org/10.1016/S0041-0101(98)00166-4>
19. Kusserow H, Unger T. Vasoactive peptides, their receptors and drug development. Basic Clin Pharmacol Toxicol 2004; 94:5–12. <https://doi.org/10.1111/j.1742-7843.2004.pto940103.x>
20. Langlois C, Letourneau M, Lampron P, St-Hilaire V, Fournier A. Development of agonists of endothelin-1 exhibiting selectivity towards ETA receptors. Br J Pharmacol 2003; 139:616–22. <https://doi.org/10.1038/sj.bjp.0705252> <PubMed>
21. Liu S, Premont RT, Kontos CD, Huang J, Rockey DC. Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein beta-gamma subunit signaling to protein kinase B/Akt. J Biol Chem 2003; 278:49929–35. <https://doi.org/10.1074/jbc.M306930200>
22. O’Callaghan D, Gaine SP. Bosentan: a novel agent for the treatment of pulmonary arterial hypertension. Int J Clin Pract 2004; 5:69–73. <https://doi.org/10.1111/j.1368-5031.2004.0098.x>
23. Patočka J, Měrka V, Hrdina V, Hrdina R. Endothelins and sarafotoxins: peptides of similar structures and different function. Acta Med (Hradec Králové) 2004; 47:157–62.
24. Peishoff CE, Janes RW, Wallace BA. Comparison of the structures of the endothelin A receptor antagonists BQ123 and N-methyl leucine BQ123 with the crystal structure of the C-terminal tail of endothelin-1. FEBS Lett 1995; 374:379–83.
25. Pinet F. What is the role of endothelin system? (Article in French). Med Sci (Paris) 2004; 20:339–45. <https://doi.org/10.1051/medsci/2004203339>
26. Potaczek DP, Sanak M Endothelin-biosynthesis, function and role in cardiovascular diseases. (Article in Polish). Pol Arch Med Wewn. 2002; 108:703–14.
27. Rubanyi GM, Botelho LH. Endothelins. FASEB J 1991; 5:2713–20. <https://doi.org/10.1096/fasebj.5.12.1916094>
28. Sharma M, Teerlink JR. A rational approach for the treatment of acute heart failure: current strategies and future options. Curr Opin Cardiol 2004; 19: 254–63. <https://doi.org/10.1097/00001573-200405000-00011>
29. Sun XY, Hedner T, Feng Q, Edvinsson L. Inhibition of endothelin (ET-1) induced pressor responses by the endothelin (ETA) receptor antagonist FR139317 in the pithed rat. Blood Press 1992; 1:108–12. <https://doi.org/10.3109/08037059209077501>
30. Takasaki C. Sarafotoxin (Article in Japanese) Seikagaku 1993; 65:189–93.
31. Tovar JM, Gums JG. Tezosentan in the treatment of acute heart failure. Ann Pharmacother 2003; 37:1877–83. <https://doi.org/10.1345/aph.1D080>
32. Yanagisawa M, Kurihara H, Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411–5. <https://doi.org/10.1038/332411a0>
33. Yukimura T, Yamashita Y, Miura K et al. Renal vasodilating and diuretic actions of a selective endothelin ETB receptor agonist, IRL1620. Eur J Pharmacol 1994; 264:399–405. <https://doi.org/10.1016/0014-2999(94)00501-X>
34. Weiser E, Wollberg Z, Kochva E, Lee SY. Cardiotoxic effects of the venom of the burrowing asp, Atractaspis engaddensis (Atractaspididae, Ophidia). Toxicon 1984; 22:767–74. <https://doi.org/10.1016/0041-0101(84)90159-4>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive